## First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer **Key Point:** Paclitaxel + Carboplatin is the gold-standard first-line regimen for advanced-stage epithelial ovarian cancer following optimal cytoreductive surgery. ### Rationale for Paclitaxel + Carboplatin **High-Yield:** This combination is based on landmark trials (GOG-111, ICON3) demonstrating superior outcomes compared to cyclophosphamide-based regimens. The regimen is: - **Efficacy:** Response rates 60–80% in optimally debulked disease - **Tolerability:** Manageable toxicity profile with standard supportive care - **Standard dosing:** Paclitaxel 175 mg/m² IV over 3 hours + Carboplatin AUC 5–6 IV, every 21 days for 6 cycles - **Advantage over cisplatin:** Carboplatin has superior tolerability (less nephrotoxicity, ototoxicity, neurotoxicity) while maintaining efficacy ### Bevacizumab Addition **Clinical Pearl:** In patients with stage IV or suboptimally debulked stage III disease, bevacizumab (anti-VEGF) is added to paclitaxel + carboplatin and continued as maintenance therapy (GOG-218, ICON7 trials). However, in optimally debulked disease, bevacizumab is not routinely added unless high-risk features are present. ### Comparison with Alternatives | Regimen | Role | Comment | |---------|------|----------| | Paclitaxel + Carboplatin | First-line (standard) | Gold standard for all stages | | Docetaxel + Cisplatin | Alternative if carboplatin contraindicated | More toxic; not preferred | | Topotecan monotherapy | Recurrent/platinum-resistant disease | Not for first-line | | Gemcitabine + Carboplatin | Recurrent disease (selected cases) | Not standard first-line | **Mnemonic:** **TAC** = Taxane (Paclitaxel) + Alkylating agent (Carboplatin) = **T**he **A**dvanced **C**hoice for ovarian cancer. [cite:Williams Gynecology 3e Ch 34]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.